


# (12) UK Patent Application (19) GB (11) 2 057 882 A

- (21) Application No 8038541  
 (22) Date of filing 2 Apr 1980  
 (30) Priority data  
 (31) 1383/79  
 (32) 4 Apr 1979  
 (33) Denmark (DK)  
 (43) Date of issue  
 8 Apr 1981  
 (51) INT CL<sup>3</sup> (as given by ISA)  
 A61K 39/116 39/102  
 C12N 1/20  
 (52) Domestic classification  
 A5B 102 132 136 137 AA  
 AB AC  
 (56) Documents cited by ISA  
 SE A 7811192-9  
 DE A 2725204  
 DE A 2825464  
 Nordisk  
 Veterinärmedicin, vol 28,  
 issued 1976, pp.337-348  
 International Journal of  
 Systematic Bacteriology,  
 vol 28, issued 1978,  
 pp.20-26  
 American Journal of  
 Public Health and the  
 Nations Health, vol 36,  
 issued 1946, pp.371-376  
 (58) Field of search by ISA  
 INT CL 1 2 3  
 A61K 39/02 06 10 102  
 116 39; C12B 3/12 3/14;  
 C12K 1/06 3/00 5/00;  
 C12N 1/20  
 US CL 195:99 100;  
 424:92; 435:253  
 (71) Applicants  
 Nordisk Droge &  
 Kemikalie A/S (Northern  
 Drugs & Chemicals Ltd.),  
 Ragnagade 9, DK-2100  
 Copenhagen OE,  
 Denmark  
 (72) Inventors  
 Joergen Fogh  
 Bjarne Nielson  
 Hans-Joergen Riising  
 (74) Agents  
 J. A. Kemp & Co.,  
 14 South Square,  
 Grays Inn  
 London WC1R 5EU

(54) **A vaccine for combatting pleuropneumonia in pigs, and a process and a substrate for the aerobic fermentation of haemophilus pleuropneumoniae**

(57) In an improved method for combatting pleuropneumonia in pigs by administering a vaccine comprising cells of the known and generally available micro-organism Haemophilus pleuropneumoniae, parts of such cells, extracts and/or metabolism products thereof as the active ingredient, adjuvants and a buffer, the improvement consisting in the use of a Bordetella pertussis vaccine, biomass and/or extracts thereof as adjuvant, as well as the new H. pleuropneumoniae vaccine comprising a B. pertussis based adjuvant. The method and the vaccine result in an improved protection of the pigs against pleuropneumonia attacks without side-effects. Besides, a new and improved substrate called CAY-substrate for the cultivation of

microorganisms in particular the bacterium H. pleuropneumoniae, which compared to known substrates results in a substantially higher yield of biomass suitable for the production of a H. pleuropneumoniae vaccine, said substrate comprising casamino acid, yeast extract, glucose and NAD as essential ingredients and being suitable for cultivation of H. pleuropneumoniae on solid as well as in liquid media by slight modifications in the composition of the substrate. An improved process for the aerobic fermentation of H. pleuropneumoniae in a liquid medium comprising the new CAY-substrate, the fermentation being advantageously performed at a temperature of about 37°C., a pH of about 7.1 to 7.4, and at an oxygen concentration in the fermentation medium of about 8 to 12 ppm, thereby maintaining the desired oxygen concentration by variation of the stirring speed and/or of the air flow rate.



GB 2 057 882 A